1 – 3 of 3
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial
(
- Contribution to journal › Letter
- 2020
-
Mark
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
(
- Contribution to journal › Article
-
Mark
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients
(
- Contribution to journal › Article